deleted in malignant brain tumors 1 like 1 (pseudogene)Genealiases: []
Q-omics provides the consensus-scored DMBT1L1 profile across patient tissues and cancer cell-line models. DMBT1L1 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, DMBT1L1 is differentially expressed in 1, with the highest sampling consensus in HNSC. Additionally, DMBT1L1 RNA expression shows 6,467 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ACC, HNSC, and STAD as cancer lineages where DMBT1L1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DMBT1L1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DMBT1L1 survival associations across molecular data types. DMBT1L1 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DMBT1L1 RNA expression–survival associations across cancer types. High DMBT1L1 expression shows unfavorable associations in ACC, KICH, BLCA and CHOL, but favorable associations in STAD and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .007). Together, the overview and detailed table identify ACC as the clearest survival context for DMBT1L1 RNA expression.
This table summarizes DMBT1L1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for DMBT1L1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DMBT1L1 shows higher tumor expression in HNSC. The HNSC box plot shows higher DMBT1L1 RNA expression in tumor versus normal tissue (log2 FC = +0.009, t-test p = .010).
This table shows molecular features associated with DMBT1L1 in patient tissues and cancer cell lines. In patient samples, DMBT1L1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
